🚀 EUFOREA Unveils the NEW Biologics Pocket Guide – A Game Changer! 📖✨ скачать в хорошем качестве

🚀 EUFOREA Unveils the NEW Biologics Pocket Guide – A Game Changer! 📖✨

Since the last decade, the treatment of patients with severe uncontrolled asthma and/or severe uncontrolled chronic rhinosinusitis with nasal polyps has been revolutionised. The game changer has been the advent of biologics or monoclonal antibodies. Several biologics are recommended in the international guidelines of care of asthma and CRSwNP but this area is complex. Physicians dealing with severe airway inflammation are not always aware of which biologic is indicated for each condition, and what they should consider in a specific patient with severe illness. Therefore riding to the rescue, EUFOREA has now come up with a new Pocket Guide for Biologics. It aims to guide physicians through the jungle of available biologics for both conditions - asthma and CRSwNP. It also highlights the similarities and differences in biologics used for both conditions. Download your copy here: https://www.euforea.eu/news/biologics... To tell us more about this achievement, EUFOREA invites Professor Wytske Fokkens (Professor in Otorhinolaryngology at the Academic Medical Centre, Amsterdam, and EUFOREA CRS / EPOS Chair) and Professor Dame Valerie Lund (Professor Emeritus of Rhinology at the Ear Institute, at University College London. She is also Honorary Consultant ENT Surgeon at the Royal National Throat, Nose and Ear Hospital also in London) to this EUFOREA News show episode. 🎙️ Interview with Prof. Wytske Fokkens: 2:11 Why did you feel there was the need to develop a Pocket Guide on Biologics for CRSwNP and for asthma? 3:39 How do you think this new Pocket Guide on biologics will help primary care and secondary caretakers dealing with asthma and/or CRSwNP? 5:02 What do you like most about this new Pocket Guide? 5:54 How often do you guess this pocket guide be updated in the future given the dynamic landscape of biologics? 🎙️ Interview with Prof. Dame Valerie Lund: 6:59 Why do you feel there was the need to develop a Pocket Guide on Biologics for asthma and for CRSwNP? 8:39 Why bother with putting the upper and lower respiratory tracts together? 10:16 Who is the pocket guide aimed at? 11:12 Does the pocket guide address mainly type 2 inflammation and are all nasal polyps type 2 dominant? This pocket guide was developed with the support of unrestricted educational grants from Novartis and Sanofi Regeneron. -------------------------------------------------------------------------------------------------------------------------- 📽 Subscribe to our YouTube Channel for our latest videos on Allergies and Airway Diseases http://bit.ly/3eMvc3E -------------------------------------------------------------------------------------------------------------------------- 📧 Get in touch with the EUFOREA team for any questions http://bit.ly/2OtlIQp -------------------------------------------------------------------------------------------------------------------------- 📌 EUFOREA is an international non-profit organisation aiming to implement optimal patient care for allergies and airway diseases (asthma, chronic rhinosinusitis, rhinitis) and comorbidities through education, research and advocacy. #euforea 📍Follow us on social media Twitter: http://bit.ly/38wrrM7 LinkedIn: http://bit.ly/2OqtWsf Instagram: http://bit.ly/3TGB5jM ​Facebook: http://bit.ly/3cnNyFF Spotify (podcast): https://bit.ly/3yBa2l3